Drug Trial Radar · NCT07862530
Neoadjuvant RP2 + Nivolumab in Patients With Melanoma
Last checked: Nov 19, 2026Latest source record: Oct 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
34
Planned (sponsor's estimate)
Start
Dec 31, 2026
Primary completion
Feb 27, 2028
Study completion Dec 31, 2033
Sponsor
- Lead sponsor
- Yana NajjarAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Replimune, Inc.
- First posted
- Oct 7, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase II study is being done to determine whether a new combination of therapies is safe and effective for adults to treat Melanoma before surgery. The two therapies that will be combined in this study are nivolumab and RP2. Nivolumab is a standard treatment for this type of cancer. Nivolumab targets and blocks a receptor called PD-1 on the surface of certain immune cells called T-cells. Blocking PD-1 may activate T-cells to find and kill cancer cells. RP2 is a new treatment that is not yet FDA approved to treat this cancer. RP2 is a herpes simplex virus (a microscopic life form commonly known as the "cold sore virus") that has been changed in the laboratory to grow in and destroy cancer cells and to activate (turn on) the immune system to attack the cancer cells.
Conditions
- MelanomaCutaneous Melanoma Resectable, Melanoma
Interventions
RP2 (vusolimogene oderparepvec)Drug
RP2 (vusolimogene oderparepvec) RP2 will be injected directly into the tumor every 2 weeks for three doses before surgery.
NivolumabDrug
Nivolumab will be administered by intravenous infusion at a dose of 240 mg every 2 weeks for 3 doses during the neoadjuvant period, followed by 480 mg every 4 weeks for 11 doses during the adjuvant period.
Definitive Surgical ResectionProcedure
Participants will undergo definitive surgical resection of all clinically resectable melanoma lesions following completion of neoadjuvant treatment with RP2 and nivolumab. Surgery will be performed according to standard clinical practice and institutional guidelines. Resected tumor tissue and, where applicable, involved lymph nodes will be collected and evaluated for pathologic response and other study-related assessments.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Major Pathologic Response Rate (MPR)Time frame: At the time of definitive surgery, approximately 8 to 10 weeks after initiation of neoadjuvant treatment.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.